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A B S T R A C T
Purpose
Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efﬁcacy is
a randomized controlled trial using amultiarm, multistage, platform design. It recruits menwith high-
risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy.
We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early
at interim analysis on the basis of failure-free survival.
Patients and Methods
Standard of care (SOC) was hormone therapy continuously (metastatic) or for $ 2 years (non-
metastatic); prostate (6 pelvic node) radiotherapy was encouraged for menwithout metastases. Cel
400 mg was administered twice a day for 1 year. Zoledronic acid (ZA) 4 mg was administered for six
3-weekly cycles, then 4-weekly for 2 years. Stratiﬁed random assignment allocated patients 2:1:1 to
SOC (control), SOC+Cel, or SOC+ ZA+Cel. The primary outcomemeasurewas all-causemortality.
Results were analyzed with Cox proportional hazards and ﬂexible parametric models adjusted for
stratiﬁcation factors.
Results
A total of 1,245 men were randomly assigned (Oct 2005 to April 2011). Groups were balanced:
median age, 65 years; 61%metastatic, 14% N+/X M0, 25% N0M0; 94% newly diagnosed; median
prostate-speciﬁc antigen, 66 ng/mL. Median follow-up was 69 months. Grade 3 to 5 adverse events
were seen in 36% SOC-only, 33% SOC + Cel, and 32% SOC + ZA + Cel patients. There were 303
control arm deaths (83% prostate cancer), and median survival was 66 months. Compared with
SOC, the adjusted hazard ratio was 0.98 (95%CI, 0.80 to 1.20; P= .847; median survival, 70months)
for SOC + Cel and 0.86 (95% CI, 0.70 to 1.05; P =.130; median survival, 76 months) for SOC + ZA +
Cel. Preplanned subgroup analyses in men with metastatic disease showed a hazard ratio of 0.78
(95% CI, 0.62 to 0.98; P = .033) for SOC + ZA + Cel.
Conclusion
These data show no overall evidence of improved survival with Cel. Preplanned subgroup analyses
provide hypotheses for future studies.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Systemic Therapy for Advanced or Metastatic
Prostate Cancer: Evaluation of Drug Efﬁcacy
(STAMPEDE) is a multiarm, multistage (MAMS),
platform, randomized controlled trial. Its novel
design1,2 allowed simultaneous assessment of
adding various therapies to standard of care
(SOC; androgen deprivation). The trial recruited
patients commencing long-term hormone ther-
apy (HT) for high-risk, locally advanced, or
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metastatic prostate cancer (CaP), either newly diagnosed or after
failure of previous local therapy. Results from STAMPEDE’s
docetaxel comparison showed major improvements in survival.3 A
companion meta-analysis4 combining data from other major in-
ternational trials5,6 conﬁrmed the usefulness of that combination,
changing world-wide practice.7,8 Here, we report outcomes after
SOC plus either celecoxib (Cel) or Cel and zoledronic acid (ZA;
Data Supplement).
Cox-2 inhibition is associated with inhibition of carcino-
genesis,9-12 and case-control studies have shown a reduced risk of
CaP.13-15 ZA has known anti-CaP effects, demonstrated both
clinically in later-stage disease16 and in vitro.17 The ﬁrst-generation
bisphosphonate clodronate improved survival when used con-
currently with long-term HT for metastatic CaP.18 The anticipated
mechanisms of action of Cox-2 inhibitors such as Cel and
bisphosphonates such as ZA were considered complementary,
allowing targeting of both bone progression and the underlying
molecular changes that lead to progression.
The MAMS design uses increasingly stringent hurdles at
interim analyses to determine whether recruitment to a compar-
ison should continue through to fully powered survival analysis.
Interim analysis was performed on failure-free survival (FFS),
primarily driven by rising prostate-speciﬁc antigen (PSA).
In 2011, at the second, preplanned activity analysis, the In-
dependent Data Monitoring Committee reviewed data, including
those on toxicity and FFS. The observed safety of Cox-2 inhibi-
tion6 ZAwas not questioned; closure to recruitment to both Cel-
containing arms was recommended because of insufﬁcient activity
on FFS, guided by a protocol-deﬁned activity target of a hazard
ratio (HR) of 0.92. The Trial Steering Committee agreed that Cel
should be stopped in both arms. The ZAwas continued because the
ZA comparison was continuing. On the committee’s recom-
mendation, comparative FFS data for the Cel-only arm were
published; follow-up continued as planned.19
Release of survival data was intended to follow publication of
survival data for the docetaxel, ZA, and docetaxel + ZA com-
parisons, which started recruitment simultaneously and passed
through all intermediate analyses.3 For the purposes of un-
derstanding, we also include some information on contempora-
neously randomly assigned patients allocated to SOC + ZA; this is
updated information on a subset of patients reported previously.3
We also contextualize our ﬁndings on Cel + ZA with summary
information from the docetaxel arms in STAMPEDE, because that
treatment is now an increasingly used SOC.
PATIENTS AND METHODS
The trial, detailed previously,2,3,19-20 was run according to Good Clinical
Practice guidelines and the Declaration of Helsinki, with relevant regu-
latory and ethics approvals.
Study Design and Participants
A MAMS platform approach was used.1,21 Eligible patients had CaP
that was newly diagnosed and either metastatic, node positive, or high-risk
locally advanced (with$ 2 of T3/4, Gleason 8 to 10, and PSA$ 40 ng/mL).
Eligibility criteria also included that the patients had been treated pre-
viously with radical surgery or radiotherapy (RT) now relapsing with high-
risk features. All were initiating long-term HT within 12 weeks before
random assignment. Patients were required to be ﬁt for chemotherapy with
no history of severe cardiovascular disease. All gave written informed
consent.
Random Assignment and Masking
A computerized algorithm implemented minimization-based ran-
dom assignment (random element, 20%), stratifying for hospital, age,
presence of metastases, planned RT use, nodal involvement, WHO per-
formance status, planned HT type, and regular aspirin and/or nonsteroidal
anti-inﬂammatory drug (NSAID) use. Allocation was 2:1:1 for open-label
SOC-only, SOC + Cel, and SOC + ZA + Cel.
Treatment
HTwas lifelong for patients with metastatic disease and$ 2years for
patients with nonmetastatic disease. HT was with gonadotropin-releasing
hormone agonists or antagonists or orchidectomy; patients with
nonmetastatic disease could receive oral anti-androgens alone; patients
with metastatic disease could undergo orchidectomy. RT was encouraged
for patients with nonmetastatic disease 6 to 9 months after random
assignment.22
Cel was given orally 400 mg twice a day for 1 year after regulatory
authority advice after withdrawal of another Cox-2 inhibitor, rofecoxib. ZA
was planned for# 2 years, given as outpatient infusions at 4 mg/15 min on
approximately 66 occasions, starting once every 3 weeks for six cycles then
once every 4 weeks. The protocol described modiﬁcations for adverse
events (AEs). Either treatment was to stop for intolerable AEs or an FFS
event.
Follow-Up
Follow-up, including PSA tests, was every 6 weeks for 6 months,
then every 12 weeks to 2 years, every 6 months to 5 years, then annually.
Additional tests were at the investigators’ discretion. Common Toxicity
Criteria version 3.01 was used to grade AEs; serious AEs were reported
promptly by sites.
Primary and Secondary Outcomes
The primary outcome measure, survival, was time from random
assignment to death from any cause. The intermediate primary outcome
measure, FFS, was time from random assignment to ﬁrst evidence of either
biochemical failure; local, lymph node, or distant metastatic progression;
or death as a result of CaP. Biochemical failure was determined as a rise in
PSA $ 4 ng/mL and 50% above the lowest reported PSA within 24 weeks
after random assignment, or failure to decrease by 50% from the starting
PSA during this time. When possible, the cause of death was determined by
blinded central review. Death as a result of CaP was recorded when
classiﬁed by the reviewer as deﬁnitely or probably CaP; the site in-
vestigator’s determination was used for 11 of 584 deaths (2%), with in-
sufﬁcient data available for central review; deaths without reported cause
were classiﬁed as non-CaP.
Statistical Design and Analysis
We assumed a median FFS of 2 years and a survival of 4 to 5 years for
control subjects and targeted a 25% relative improvement (HR, 0.75) in
FFS and overall survival (OS) for each pairwise comparison of research
arm to control arm. The Stata program nstage (Stata, College Station, TX)
allowed the MAMS design with three intermediate activity analyses on the
basis of FFS and an efﬁcacy analysis on the basis of survival. The latter had
90% power and a 2.5% one-sided a, requiring approximately 400 control
arm deaths; the former each had 95% power and increasingly stringent
one-sided as of 50%, 25%, and 10%, requiring approximately 114, 216,
and 334 FFS events, respectively, and expressed as lack-of-beneﬁt stopping
guidelines.19 Only patients randomly assigned contemporaneously were
compared head to head for each pairwise comparison. Patients were
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included in the efﬁcacy analyses according to allocated treatment on an
intention-to-treat (ITT) basis, unless stated.
Accumulating data were reviewed by the Independent Data Mon-
itoring Committee. Patients allocated to the Cel arm who still met the
eligibility criteria when accrual stopped prematurely were offered
complete withdrawal and re-random assignment to an ongoing arm (this
is not one of the primary comparisons reported here); ﬁve accepted and
contribute here only a short period of data from random assignment to
withdrawal from their original allocation. Standard survival analysis
methods were used for analyses of time-to-event data in STATA version
14. Patients without the relevant event were censored when last reported
event free. Cox proportional hazards regression models, adjusted for
stratiﬁcation factors (with the exception of hospital and planned HT),
were used to estimate most relative treatment effects, with HR , 1.00
favoring the research arm. Flexible parametric models23 with ﬁve degrees
of freedom for the baseline hazard function and ﬁve degrees of freedom
for the time-dependent effect and adjusted for stratiﬁcation factors were
used to estimate medians, 5-year event rates, and restricted mean survival
time. Restricted mean survival time took primacy if there was evidence
of nonproportional hazards. The likelihood ratio test was used to test
for the presence of treatment-subgroup interactions. Fine and Gray
regression models were used for competing risk analysis of CaP-speciﬁc
survival. All conﬁdence intervals are at 95%. Prespeciﬁed analyses ex-
amined consistency of treatment effect by stratiﬁcation factors, cate-
gorized Gleason score (# 7, $ 8, or unknown), timing of random
assignment (newly diagnosed or recurrent after previous local therapy),
and, as a continuous variable, pre-HT PSA. A P value , .10 was taken
to be indicative of possible heterogeneity. A preplanned subgroup anal-
ysis of M1 patients at random assignment was included in the statisti-
cal analysis plan and the complementary M0 group. Sensitivity
analyses dividing patients by whether they could have received the
maximal duration of Cel (earlier), or not (later), were considered (Data
Supplement).
Median follow-up was estimated by reverse censoring on death, in
which survival is treated as the event and death as censoring.
Preplanned exploratory factorial analyses of ZA and Cel, with and
without an interaction term, drew in data from those patients randomly
assigned contemporaneously to SOC + ZA.
The safety population for analysis of AEs grouped patients according
to treatment started, with sensitivity analysis on an ITT basis. Data on ﬁrst
reported symptomatic skeletal event (SSE) and osteonecrosis of the jaw are
also presented.
Allocated to Arms B, C, or E
(n = 933)
Patients randomly assigned between
October 5, 2005, and April 6, 2011
(N = 2,178)
Allocated to Arms A, D, or F
(allocation 2:1:1)
(n = 1,245)
Analyzed
(n = 6)
Excluded, no AE
assessment (0 F)
Analyzed
(n = 625)
Excluded, no AE assessment
(6 A, 8 D, 8 F)
Analyzed
(n = 296)
Excluded, no AE assessment
(3 D, 0 F)
Analyzed
(n = 293)
Excluded, no AE assessment
(0 F)
Allocated to Arm F
(SOC + ZA + Cel)
  Received ZA
  Received Cel
  Did not receive ZA or Cel
(n = 311)
(n = 299)
(n = 294)
(n = 11)
Alive; data in past year
Alive; no data in past year
Died
(n = 238)
(n = 81)
(n = 303)
Alive; data in past year
Alive; no data in past year
Died
(n = 109)
(n = 60)
(n = 143)
Alive; data in past year
Alive; no data in past year
Died
(n = 119)
(n = 54)
(n = 138)
Analyzed
(n = 622)
Analyzed
(n = 312)
Analyzed
(n = 311)
ZA-only reported
(n =6 [6 F])
SOC-only reported
(n = 647 [622 A; 14 D; 11 F])
Cel-only reported
(n = 299 [298 D; 1 F])
ZA + Cel reported
(n =293 [293 F])
Allocated to Arm A (SOC only; n = 622) Allocated to Arm D
(SOC + Cel)
  Received Cel
  Did not receive Cel
(n = 312)
(n = 298)
(n = 14)
Fig 1. CONSORT ﬂow diagram depicting the ﬂow of patients who joined the STAMPEDE trial while these speciﬁc comparisons were open to recruitment. Further
context is given in the Data Supplement. A, standard of care (SOC); AE, adverse event; Cel, celecoxib; D, SOC + Cel; F, ZA + SOC + Cel; ZA, zoledronic acid.
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Table 1. Baseline Characteristics, by Arm
Characteristic SOC (n = 622) SOC + Cel (n = 312) SOC + ZA + Cel (n = 311)
Age, years
Median (IQR) 65 (59-70) 66 (61-71) 65 (60-70)
Range 41-82 41-80 37-94
PSA, ng/mL
Median (IQR) 67 (24-197) 57 (22-183) 70 (23-182)
Range 1-15747 2-5000 0-5103
Days from diagnosis
Median (IQR) 75 (50-99) 71 (53-97) 74 (54-101)
Range 0-3594 7-3219 7-3613
Missing 3 1 0
Pain from prostate cancer, No. (%)
Absent 497 (82) 272 (89) 263 (86)
Present 111 (18) 34 (11) 43 (14)
Missing 14 6 5
WHO performance status, No. (%)
0 480 (77) 240 (77) 242 (78)
1-2 142 (23) 72 (23) 69 (22)
T category at random assignment, No. (%)
T0 4 (1) 1 (0) 5 (2)
T1 10 (2) 5 (2) 4 (1)
T2 55 (9) 18 (6) 31 (10)
T3 399 (64) 208 (67) 183 (59)
T4 107 (17) 54 (17) 67 (22)
TX 47 (8) 26 (8) 21 (7)
N category at random assignment, No. (%)
N0 282 (45) 142 (46) 141 (45)
N+ 302 (49) 148 (47) 150 (48)
NX 38 (6) 22 (7) 20 (6)
Metastases, No. (%)
None 245 (39) 124 (40) 121 (39)
Any metastases 377 (61) 188 (60) 190 (61)
Bone metastases 330 (53) 162 (52) 159 (51)
Liver metastases 8 (1) 2 (1) 8 (3)
Lung metastases 18 (3) 5 (2) 10 (3)
Nodal metastases 116 (19) 50 (16) 64 (21)
Other metastases 24 (4) 21 (7) 12 (4)
Broad disease grouping, No. (%)
Newly diagnosed N0M0 144 (23) 75 (24) 66 (21)
Newly diagnosed N+M0 78 (13) 41 (13) 45 (14)
Newly diagnosed M1 360 (58) 177 (57) 180 (58)
Previously treated M0 23 (4) 8 (3) 10 (3)
Previously treated M1 17 (3) 11 (4) 10 (3)
Gleason sum score, No. (%)
# 7 154 (25) 80 (26) 84 (27)
8-10 409 (66) 205 (65) 193 (62)
Unknown 59 (9) 27 (9) 34 (11)
Aspirin or NSAID use, No. (%)
No 470 (76) 238 (76) 234 (75)
Yes 152 (24) 74 (24) 77 (25)
Planned or current HT, No. (%)
Orchidectomy 4 (1) 1 (0) 1 (0)
LHRH based 609 (98) 305 (98) 303 (98)
Bicalutamide 9 (1) 6 (2) 7 (2)
Time to starting HT, days
Median (IQR) 238 (260 to 215) 232 (254 to 216) 234 (258 to 215)
Range 2105 to 77 297 to 31 2153 to 46
Missing 1 0 0
Planned anti-androgen use, No. (%)
No 59 (10) 29 (10) 27 (9)
Short-term anti-androgen 438 (73) 221 (73) 228 (77)
Long-term anti-androgen 101 (17) 52 (17) 41 (14)
Missing 24 10 15
Radiotherapy planned, No. (%)
No 475 (76) 241 (77) 242 (78)
Yes 147 (24) 71 (23) 69 (22)
(continued on following page)
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RESULTS
Accrual and Patient Characteristics
Between October 5, 2005, and April 6, 2011, 1,245 men were
randomly assigned 2:1:1 from 80 sites in the United Kingdom and
two sites in Switzerland: 622 to SOC-only, 312 to SOC + Cel, and
311 to SOC + ZA + Cel. Data were frozen on December 15, 2015.
Figure 1 presents the CONSORT ﬂow diagram and Table 1, baseline
characteristics; the Data Supplement contextualizes these arms
overall. Median follow-up was 69 months. Median age was 65 years
andmedian PSAwas 66 ng/mL, and 65% had a Gleason sum score of
8 to 10. One thousand one hundred sixty-six patients (94%) were
newly diagnosed, and 717 (61%) were metastatic at entry; 38 of 79
(48%) who were recurrent after local treatment had metastases.
Treatment
For SOC+Cel and SOC+ZA+Cel, respectively, median time to
starting Cel was 0.9 and 1.7 weeks after random assignment, and 6.5
and 7.1 weeks after starting HT; 14 and 17 patients, respectively, did
not report starting Cel. Median duration of Cel was 8.3 months for
SOC + Cel and 8.0 months for SOC + ZA + Cel (Data Supplement).
Themost common reason for stoppingwas treatment completion: 120
of 298 (40%) and 116 of 293 (40%), respectively (Data Supplement).
Median ZA starting time was 1.7 weeks after random as-
signment, and 7.1 weeks from starting HT. ZAwas not reported as
having started in 12 patients. Median ZA duration was 15 months
(Data Supplement). Progression was the most common reason
(130 of 297) for stopping treatment early; 100 of 297 (34%)
completed the planned 2 years (Data Supplement).
SOC RTwas reported in 158 of 622 SOC-only (25%), 70 of 312
SOC + Cel (22%), and 56 of 311 SOC + ZA + Cel (18%). In patients
with nonmetastatic disease, 140 of 245 (57%), 54 of 124 (44%), and 51
of 121 (42%), respectively, reported primary site RT (Data Supplement).
Survival
There were 303 deaths (251 deaths related to CaP; 83%) in
the SOC-only group; median survival was 66 months; and 5-year
Table 1. Baseline Characteristics, by Arm (continued)
Characteristic SOC (n = 622) SOC + Cel (n = 312) SOC + ZA + Cel (n = 311)
Smoker, No. (%)
No 530 (86) 270 (88) 269 (87)
Yes 85 (14) 38 (12) 39 (13)
Missing on cardiovascular assessment 5 3 3
Cardiovascular assessment not received 2 1 0
Diabetes, No. (%)
No 564 (91) 281 (90) 281 (91)
Yes, type 1 14 (2) 7 (2) 8 (3)
Yes, type 2 41 (7) 23 (7) 21 (7)
Missing on cardiovascular assessment 1 0 1
Cardiovascular assessment not received 2 1 0
Myocardial infarction, No. (%)
No 606 (98) 303 (97) 302 (97)
Yes, but still ﬁt for trial 12 (2) 8 (3) 7 (3)
Yes, ineligible* 0 (0) 0 (0) 1 (0)
Missing on cardiovascular assessment 2 0 1
Cardiovascular assessment not received 2 1 0
Cerebrovascular disease, No. (%)
No 612 (99) 306 (98) 306 (99)
Yes, but still ﬁt for trial 6 (1) 5 (2) 4 (1)
Missing on cardiovascular assessment 2 0 1
Cardiovascular assessment not received 2 1 0
Congestive heart failure, No. (%)
No 616 (100) 309 (99) 309 (100)
Yes, but still ﬁt for trial 2 (0) 2 (1) 1 (0)
Missing on cardiovascular assessment 2 0 1
Cardiovascular assessment not received 2 1 0
Angina, No. (%)
No 598 (97) 301 (97) 298 (96)
Yes, but still ﬁt for trial 20 (3) 10 (3) 12 (4)
Missing on cardiovascular assessment 2 0 1
Cardiovascular assessment not received 2 1 0
Hypertension, No. (%)
No 404 (65) 198 (64) 205 (66)
Yes, but still ﬁt for trial 215 (35) 113 (36) 105 (34)
Missing on cardiovascular assessment 1 0 1
Cardiovascular assessment not received 2 1 0
Abbreviations: Cel, celecoxib; HT, hormone therapy; IQR, interquartile range; LHRH, luteinizing hormone–releasing hormone; NSAID, nonsteroidal anti-inﬂammatory
drug; PSA, prostate-speciﬁc antigen; SOC, standard of care; ZA, zoledronic acid.
*One patient in arm Fwas conﬁrmed as ineligible with a history of M1 (patient 14052). The patient received no treatment and was withdrawn (retrospectively) on day of
random assignment.
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Fig 2. Failure-free and overall survival, by research comparison. Kaplan-Meier plots showing time to event for the deﬁnitive primary outcome measure (overall survival)
and intermediate primary outcomemeasure (failure-free survival). (A) Failure-free survival in the celecoxib comparison. (B) Overall survival in the celecoxib comparison. (C)
Failure-free survival in the ZA + celecoxib comparison. (D) Overall survival in the ZA + Cel comparison. Cel, celecoxib; SOC, standard of care; ZA, zoledronic acid.
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survival was 53%. There was no evidence of a survival advantage
for SOC + Cel (HR, 0.98; 95%CI, 0.80 to 1.20; P = .847: 143 deaths
[117 deaths related to CaP; 82%]); median survival was 70 months;
and 5-year survival was 54%. Nor was there evidence of a survival
advantage for SOC + ZA + Cel (HR, 0.86; 95% CI, 0.70 to 1.05; P =
.130: 138 deaths [103 deaths related to CaP; 75%]); median
survival was 76 months; and 5-year survival was 59% (Figs 2B and
2D). There was no evidence of nonproportional hazards data.
Preplanned subgroup analyses in 755 M1 patients included 355
and 349 deaths for the two comparisons. This included 245 deaths in
SOC-only; median survival was 43 months; and 5-year survival was
37%. There were 110 deaths in the SOC +Cel group (HR, 0.94; 95%
CI, 0.75 to 1.18; P = .602); median survival was 43 months; and
5-year survival was 40%. There were 104 deaths in the SOC + ZA +
Cel group (HR, 0.78; 95% CI, 0.62 to 0.98; P = .033); median
survival was 55months; and 5-year was survival 47% (Fig 3). Similar
comparisons in M0 patients are relatively immature, with , 100
deaths per comparison. However, we found some indication of
possible heterogeneity of treatment effect by metastatic status at
random assignment for SOC + ZA + Cel (P = .072; Fig 4). Apart
from nodal status (P = .061), there was no other evidence of het-
erogeneity of treatment effect for either comparison (Fig 4).
Exploratory analysis of the main effects of Cel and ZA in-
dividually in a single factorial model without a treatment-
interaction term did not associate either drug with a survival
advantage (Cel HR, 0.97; 95% CI, 0.83 to 1.13; P = .670; and ZA
HR, 0.89; 95% CI, 0.77 to 1.04; P = .150). The factorial model,
including a treatment-interaction term, found no evidence of
treatment interaction (P = .788).
In patients with metastatic disease, the single factorial model
without a treatment-interaction term showed no advantage to Cel
(HR, 0.92; 95% CI, 0.77 to 1.09; P = .341) or ZA (HR, 0.86; 95%
CI, 0.72 to 1.02; P = .083). A further exploratory factorial model,
including a treatment-interaction term, found no evidence of
treatment interaction (P = .748).
FFS
Figures 2A and 2C present an FFS plot for each comparison.
PSA failure was the most common for each arm (Data Supple-
ment). There were 457 FFS events for SOC-only; median FFS was
20 months; and 5-year FFS was 26%. SOC + Cel had 213 events
with no evidence of improved FFS (HR, 0.87; 95% CI, 0.74 to 1.03;
P = .102); median FFS was 22 months; and 5-year FFS was 29%.
SOC + ZA + Cel had 213 events and some evidence of a difference
compared with SOC (HR, 0.84; 95% CI, 0.72 to 0.99; P = .043);
median FFSwas 24months; and 5-year FFSwas 30%. There was no
evidence of nonproportional hazards.
There was evidence of heterogeneity of treatment effect by
predeﬁned subgroups including performance status and baseline
NSAID and/or aspirin use for both comparisons, in addition to
recurrent disease for SOC + Cel and Gleason score and age at
random assignment for SOC + ZA +Cel (Data Supplement). In the
subgroup analyses by baseline metastatic status, the estimates for
FFS in SOC + ZA + Cel were HR, 0.77 (95% CI, 0.63 to 0.93) in
metastatic disease and HR, 1.02 (95% CI, 0.75 to 1.39) in non-
metastatic disease, but there was no evidence of heterogeneity
(P = .119).
Factorial analyses without an interaction term in the 643
earlier patients suggested effects on FFS in patients with meta-
static disease from both Cel (HR, 0.85; 95% CI, 0.71 to 1.01; P =
.069) and ZA (HR, 0.84; 95% CI, 0.70 to 1.00; P = .052), but no
evidence of interaction between treatments in a further model
(P = .942).
CaP-Specific Survival
Of 584 deaths, 471 (81%) were a result of CaP; a higher
proportion of deaths was attributed to CaP in patients with
metastatic disease (381 of 459 deaths [83%] in 755 M1 patients,
and 90 of 125 deaths [72%] in 490 patients with nonmetastatic
disease). Adjusted competing risk regression for CaP-speciﬁc
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Fig 3. Overall survival for SOC + Cel + ZA
versus SOC in patients with metastatic disease.
Kaplan-Meier plot showing overall survival for the
ZA + Cel comparison in patients who presented
with metastatic disease at random assignment.
Cel, celecoxib; SOC, standard of care; ZA, zole-
dronic acid.
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survival showed no evidence of advantage over SOC-only for
SOC + Cel (sub-HR, 0.97; 95% CI, 0.77 to 1.23; P = .782) but an
advantage for SOC + ZA + Cel (sub-HR, 0.74; 95% CI, 0.59 to
0.94; P = .014). For patients with metastatic disease, the sub-HR
for SOC + Cel was 0.91 (95% CI, 0.71 to 1.18), and the sub-HR
for SOC + ZA + Cel was 0.64 (95% CI, 0.49 to 0.83); for patients
with nonmetastatic disease, the sub-HR for SOC + Cel was 1.44
(95% CI, 0.86 to 2.40), and the sub-HR for SOC + ZA + Cel was
1.31 (95% CI, 0.78 to 2.18).
Of deaths not related to CaP, 23 of 113 (20%) were classiﬁed as
cardiovascular disease: nine of 52 (17%) SOC-only, three of 26
(12%) SOC + Cel, and 11 of 35 (31%) SOC + ZA + Cel.
SSEs
A total of 207 of 622 SOC-only patients reported one or more
SSEs. There was no evidence that the time to ﬁrst SSE was im-
proved with SOC + Cel (90 of 312 patients reported SSE: HR,
0.85; 95% CI, 0.66 to 1.08; P = .186) or with SOC + ZA + Cel
(95 of 311 patients reported SSE: HR, 0.84; 95% CI, 0.66 to1.07;
P = .162).
AEs
In per protocol analyses of safety, one third reported worst AE
ever as grade $ 3: 222 of 625 (36%) SOC-only, 98 of 296 (33%)
SOC + Cel, and 95 of 293 (32%) SOC + ZA + Cel (Table 2). In 799
patients with AE assessment at approximately 1 year after random
assignment, the proportions with grade $ 3 AE were 43 of 398
(11%) SOC-only, 16 of 200 (8%) SOC + Cel, and 13 of 196 (7%)
SOC + ZA + Cel, mostly related to SOC with androgen deprivation
therapy. Patterns and levels of AEs were similar in the ITT pop-
ulation. There were six reported cases of osteonecrosis of the jaw,
all in the SOC + ZA + Cel group.
Second-Line Treatment
The Data Supplement lists time from FFS event to next
treatment and time to any of the ﬁve life-extending therapies in
castrate-refractory prostate cancer (available agents with proven
survival gain). There was no evidence among arms of a difference
in time to either any therapy or life-extending therapies (Data
Supplement). There were no reports of patients allocated to SOC-
only switching to Cel after progression; 82 and 22 patients in the
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Fig 4. Forest plots of treatment effect on survival within subgroups, by research comparison, showing assessment of consistency of the treatment effect on overall
survival in preplanned subgroups for (A) the Cel comparison and (B) the ZA + Cel comparison. The number of deaths and the number of patients are shown by arm for each
treatment level, together with an adjusted hazard ratio and a test for heterogeneity of the treatment effect. Cel, celecoxib; Mets, metastases; NSAID, nonsteroidal anti-
inﬂammatory drug; PS, performance status; RT, radiotherapy; SOC, standard of care; ZA, zoledronic acid.
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SOC-only group and the SOC + Cel group, respectively, reported
using ZA after progression.
DISCUSSION
We report the ﬁndings of two randomized comparisons from
STAMPEDE, a MAMS-platform trial, in 1,245 patients starting
long-term ﬁrst-line HT, with a median follow-up of . 5 years.
These two Cel comparisons show no overall evidence that Cel,
alone or combined with ZA, improved survival or FFS compared
with SOC. However, a preplanned subgroup analysis suggested the
possibility of beneﬁt in terms of both survival and FFS for SOC +
Cel + ZA over SOC alone in M1 patients at random assignment,
although the test for interaction was not signiﬁcant at a traditional
5% signiﬁcance level.
Importantly, follow-up continued after accrual to Cel stopped.
There is no bias in the reporting time of these comparisons; we
report them, as planned, straight after survival results from the
other arms that started contemporaneously. Data return rates are
good, with most patients known to be alive having reported data in
the past year.
Although recruitment to these comparisons was terminated
early, there are still three quarters the number of control arm
deaths that would have triggered this survival analysis had the
comparisons passed all three interim analyses (n = approximately
300 of 400).
Results for the combination of Cel and ZA are intriguing and
unexpected, given that we observed no evidence of improvement in
OS or FFS with the addition of either Cel or ZA alone. Un-
fortunately, no further comparative data that would help directly in
interpretation are expected. No other powered randomized con-
trolled trial combining bisphosphonates and Cox-2 inhibitors are
listed on trial registers; studies listed are nonrandomized or small
or they terminated early. Our data fall short of deﬁnite evidence
that this is a real effect; tests for interaction typically lack power,
particularly in subgroups and where accrual is terminated early.
Rather, they are hypothesis generating and provoke further re-
search. Biologically, an effect by directly targeting tumor and/or
host cells, particularly of stromal and immune lineage, is not
implausible.24-26
The observed effect on survival of combined Cel and ZA in the
metastatic setting is of similar magnitude to that reported for
docetaxel in the STOPCaP (Systemic Treatment Options for
Prostate Cancer) meta-analysis,4 although the observed effect on
FFS is much less pronounced (Table 3 and Data Supplement).
There are reports of anticancer activity with the nonsteroidal anti-
inﬂammatory agent diclofenac,24 and STOPCaP suggests an overall
beneﬁt of bisphosphonates in metastatic disease, albeit driven by
one trial of sodium clodronate.4
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We deﬁned survival as the deﬁnitive outcome measure, D,
and FFS as the intermediate outcome measure, I. When this trial
was ﬁrst designed, some fundamental principles and assumptions
were adopted, following the process for MAMS designs: (1)
a treatment that does not improve I is unlikely to sufﬁciently
improve D; (2) an improvement in I may not translate into an
improvement in D; (3) therefore, a failure to improve I by
a prespeciﬁed amount can be used as a triage for D, to allow early
stopping of recruitment, but success in improving I does not
remove the need to continue recruitment to reliably assess D; (4) I
does not need to be a surrogate for D in the strictest sense, but
only on the causal pathway; and (5) arms whose recruitment is
stopped because of failure to improve I will continue to be
followed up, and D will be reported soon after that for con-
temporaneously initiated arms.
When the trial launched in 2005, these assumptions were still
thought to be reasonable with our choices for I and D. With the
hindsight afforded by a decade of new knowledge and new data, we
now realize that in CaP and in some other cancers, and with some
interventions, there might be more discordance between FFS and
survival in some circumstances.
FFS was the interim outcome measure for Cel and ZA. The
vast majority of patients respond to HT with a fall in PSA values;
we were speciﬁcally looking for an enhancement of the time to
treatment failure by the addition of these agents, which legitimizes
FFS as an outcome measure because response was not an ap-
propriate outcome. The primary outcome measure is OS, which is
not dependent directly on PSA values, although PSA values will
have affected treatment decisions for clinicians along the way. The
multistage approach in a MAMS trial does not require a perfect
Table 2. Worst AE (grade) Reported Over Entire Time on Trial, by Treatment Reported
SOC SOC + Cel SOC + ZA + Cel SOC + ZA
Safety population
Patients included in AE analysis 625 296 293 6
Grade 1-5 AE 618 (99) 295 (100) 290 (99) 6 (100)
Grade 3-5 AE 222 (36) 98 (33) 95 (32) 2 (33)
Grade 5 AE 4 3 3 0
Most frequent AEs reported as G3-5
Endocrine disorder (including impotence, hot ﬂushes) 86 (14) 33 (11) 32 (11) 0 (0)
Musculoskeletal (including bone pain, generalized pain) 45 (7) 25 (8) 15 (5) 0 (0)
Renal (including renal impairment, UTI) 38 (6) 10 (3) 15 (5) 0 (0)
General disorder (including lethargy, fever, asthenia) 30 (5) 9 (3) 7 (2) 1 (17)
GI disorder (including diarrhea, abdominal pain,
constipation, vomiting)
20 (3) 12 (4) 15 (5) 0 (0)
Cardiac disorder (including hypertension, MI) 19 (3) 10 (3) 8 (3) 1 (17)
Respiratory disorder (including dyspnea, upper RTI) 16 (3) 7 (2) 8 (3) 0 (0)
Osteonecrosis of the jaw 0 (0) 0 (0) 6 (2) 0 (0)
ITT population
Patients according to random assignment 622 312 311 N/A
Patients included in AE analysis 616 301 303 N/A
Grade 1-5 AE 610 (99) 299 (99) 300 (99) N/A
Grade 3-5 AE 219 (36) 98 (33) 100 (33) N/A
Grade 5 AE 4 3 3 N/A
NOTE. The table summarizes the toxicities reported with each treatment. The top section is the safety population. Patients are included with the treatments they
started, hence there is a column of six patients receiving ZA only; these are patients in the combination armwho did not report starting Cel. The bottom section is the ITT
or as-allocated population. Grade 5 AEs were not necessarily treatment related, and treatment-related deaths were not always a grade 5 serious AE. Data are presented
as No. (%).
Abbreviations: AE, adverse event; Cel, celecoxib; ITT, intention to treat; MI, myocardial infarction; N/A, not applicable; RTI, respiratory tract infection; SOC, standard of
care; UTI, urinary tract infection; ZA, zoledronic acid.
Table 3. Summary Data From this Article and for Doc and ZA From Meta-Analysis
Outcome
Data Reported Here Previous Data From Meta-Analysis4
SOC + Cel (n = 312) SOC + ZA + Cel (n = 311) SOC + Doc SOC + ZA
FFS 0.87 (0.74 to 1.03) 0.85 (0.72 to 1.00) N/A N/A
OS 0.98 (0.80 to 1.20) 0.86 (0.70 to 1.05) N/A N/A
PCa-speciﬁc survival 0.97 (0.77 to 1.23) 0.76 (0.60 to 0.96) N/A N/A
FFS M1 subgroup 0.86 (0.71 to 1.04) 0.77 (0.63 to 0.93) 0.64 (0.58 to 0.70)
OS M1 subgroup 0.94 (0.75 to 1.18) 0.78 (0.62 to 0.98) 0.77 (0.68 to 0.87) 0.88 (0.79 to 0.98)
Metastatic status, FFS 0.6184 0.1088
Interaction P for OS .3455 .0724
NOTE. This table presents a summary of treatment effects in the data reported here in the context of the data for adding Doc or ZA to SOC in the recent meta-analysis.
Data are presented as hazard ratio (95% CI). For more information, see Data Supplement.
Abbreviations: Cel, celecoxib; Doc, docetaxel; FFS, failure-free survival; N/A, not applicable; OS, overall survival; PCa, prostate cancer; SOC, standard of care; ZA,
zoledronic acid.
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surrogate outcome measure, but one on the causal pathway, as FFS
is for survival. Overall, there was minimal effect on FFS, and this
translated into minimal effect on OS. In this regard, FFS was an
acceptable choice. For the comparisons added later in STAMPEDE,
we used the same deﬁnition of FFS treatment in both the abir-
aterone comparison and the enzalutamide plus abiraterone
comparison in STAMPEDE, but allowed treatment to continue
using all three types of progression (biochemical, clinical, and
radiologic); for the new metformin comparison that opened
in STAMPEDE in September 2016, we have chosen not to use
a PSA-driven outcome measure as the intermediate outcome
measure.27,28
Interpretation is further complicated by early cessation of Cel
treatment when recruitment stopped at the second activity analysis
(Data Supplement), which meant that fewer patients could receive
the planned duration of their allocated treatment. Long-term
estimation of the treatment effect on FFS of SOC + Cel versus
SOC-only in the Cel comparison is consistent with our previous
publication,19 when Cel failed to pass its second intermediate
activity threshold.
At random assignment, RTwas stated as part of the treatment
plan for approximately one quarter of M0 patients across all arms.
Around the time recruitment to these comparisons was stopped,
data were emerging from NCIC-CTG-PR.3/MRC-PR07 and
SPCG-7 that RT improved survival for men starting long-term HT
for M0 CaP.29,30 Herein, the reported use of RT in the control
group met expectations, but it was lower in both research arms.
This preferential omission of RT from the Cel-containing arms
complicates the ﬁndings, and a more favorable signal may have
been observed had RT not been preferentially omitted for un-
recorded reasons.
Approximately one half of the patients died, mostly as a result
of CaP. There were several deaths with cardiovascular causes, but
these occurred proportionally more in the combination arm.
One stratiﬁcation factor at random assignment was the use of
NSAIDs and/or aspirin, included only because of these Cel
comparisons. Both comparisons had much improved FFS in pa-
tients receiving NSAIDs and/or aspirin at baseline, but this did not
translate into evidence of a difference in survival. Baseline use of
NSAIDs and/or aspirin likely related to underlying, pre-existing
comorbidities, but this effect deserves further exploration.
Our data show no evidence of a survival advantage in adding
Cel alone for all men starting long-term HT for the ﬁrst time. We
previously also showed no evidence of a survival advantage in
adding ZA alone for the same patient group. Overall, the com-
bination of Cel and ZA had no effect. Preplanned subgroup an-
alyses may provide a hypothesis for future studies to investigate
adding Cel in settings in which ZA is already part of the SOC.
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